

Bristol-Myers Squibb Co

14:00 12 Apr 2018

Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

Bristol-Myers Squibb Co (NYSE:BMJ) shares were down Thursday while Pfizer Inc. (NYSE:PFE) rose after an analyst for Citi Investment Research said a deal between the two drugmakers isn't likely to happen.

Bristol-Myers lost 2% to US\$58.96, while Pfizer rose 1.7% to US\$36.38 in midday trade.

Citi analyst Andrew Baum said he met with Pfizer CEO Ian Read and he had "no interest" in Bristol-Myers or other major deals right now.

"In our meeting yesterday with Pfizer's CEO, COO and CSO, Pfizer made clear that they had no interest in BMJ in the absence of transformational data or de-rating of the shares," Baum was quoted as saying in a Citi research report shared with Streetinsider.com.

In February, Baum had laid out a scenario where Pfizer may look to buy its rival despite its large market cap.

The Citi analyst cut his price target to US\$70 from US\$78 after he removed a US\$8 a share M&A risk premium from his target price.

"We view our newly lowered target price as conservative given the absence of contribution from CHECKMATE-9LA in 1st line non-small cell lung cancer," Baum wrote in the report.

Investors will get a look at results next week from Bristol-Myers's Phase 3 study of Opdivo and Yervoy in patients newly diagnosed with advanced lung cancer with high tumor mutational burden.

The New York-based drugmaker will hold an investor event to discuss the lung-cancer data on Monday at 5 p.m. CT.

Teaming up with Harvard researchers

Separately, Bristol-Myers announced on Thursday that it was working on research with the Harvard Fibrosis Network of the Harvard Stem Cell Institute to develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.


"Bristol-Myers Squibb strives to develop transformational therapies that arrest or reverse the progression of fibrosis and restore organ function," said Carl Decicco, head of discovery at Bristol-Myers Squibb. "We believe this collaboration will advance fibrosis research...and the development of new therapies for patients with these debilitating conditions."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 52.41

Market Cap: \$85.73 billion

1 Year Share Price Graph



October 2018 April 2019 October 2019

Share Information

Code: BMJ

Listing: NYSE

52 week	High	Low
	59.27	42.49

Sector: Medical technology & services

Website: www.bms.com

Company Synopsis:

Bristol-Myers Squibb is a global producer and distributor of pharmaceuticals and other healthcare-related products. The merger of Bristol-Myers with Squibb in 1989 created what was then the world's second-largest pharmaceutical enterprise.

action@proactiveinvestors.com

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.